Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Friedlaender

Showing results (41-50 of 106) with videos related to

Pageof 11
Sort By:
Cancers|August 29, 2024
Advances in Personalized OncologyHiba Mechahougui, James Gutmans, Gina Colarusso, et al.
Revue Medicale Suisse|October 21, 2020
[Granulocyte-Colony Stimulating Factors as adjunctive therapy in patients with neutropenic fever]Elisa Buchs, Yves Chalandon, Alex Friedlaender, et al.
International Journal of Molecular Sciences|May 7, 2025
BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical ApplicationsHiba Mechahougui, James Gutmans, Roumaïssa Gouasmi, et al.
Therapeutic Advances in Drug Safety|April 15, 2021
Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative reviewLaure Thouvenin, Timothée Olivier, Giuseppe Banna, et al.
Frontiers in Endocrinology|August 13, 2024
Editorial: Molecular characterization of thyroid lesions in the era of "next generation" techniques: volume IIUmberto Malapelle, Claudio Bellevicine, Alex Friedlaender, et al.
Frontiers in Endocrinology|July 18, 2022
Editorial: Molecular Characterization of Thyroid Lesions in the Era of "Next-Generation" TechniquesClaudio Bellevicine, Alessia Ciarrocchi, Alex Friedlaender, et al.
Frontiers in Oncology|April 19, 2021
The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted TherapyAlex Friedlaender, Petros Tsantoulis, Mathieu Chevallier, et al.
Cancer|September 5, 2020
The METeoric rise of MET in lung cancerAlex Friedlaender, Alexander Drilon, Giuseppe Luigi Banna, et al.
Current Oncology Reports|May 30, 2023
Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung CancerJay Parekh, Kaushal Parikh, Joshua E Reuss, et al.
Biomarker Research|February 12, 2024
Oncogenic alterations in advanced NSCLC: a molecular super-highwayAlex Friedlaender, Maurice Perol, Giuseppe Luigi Banna, et al.
Pageof 11

Showing results (41-50 of 106) with videos related to

Sort By:
Pageof 11
Cancers|August 29, 2024
Advances in Personalized OncologyHiba Mechahougui, James Gutmans, Gina Colarusso, et al.
Revue Medicale Suisse|October 21, 2020
[Granulocyte-Colony Stimulating Factors as adjunctive therapy in patients with neutropenic fever]Elisa Buchs, Yves Chalandon, Alex Friedlaender, et al.
International Journal of Molecular Sciences|May 7, 2025
BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical ApplicationsHiba Mechahougui, James Gutmans, Roumaïssa Gouasmi, et al.
Therapeutic Advances in Drug Safety|April 15, 2021
Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative reviewLaure Thouvenin, Timothée Olivier, Giuseppe Banna, et al.
Frontiers in Endocrinology|August 13, 2024
Editorial: Molecular characterization of thyroid lesions in the era of "next generation" techniques: volume IIUmberto Malapelle, Claudio Bellevicine, Alex Friedlaender, et al.
Frontiers in Endocrinology|July 18, 2022
Editorial: Molecular Characterization of Thyroid Lesions in the Era of "Next-Generation" TechniquesClaudio Bellevicine, Alessia Ciarrocchi, Alex Friedlaender, et al.
Frontiers in Oncology|April 19, 2021
The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted TherapyAlex Friedlaender, Petros Tsantoulis, Mathieu Chevallier, et al.
Cancer|September 5, 2020
The METeoric rise of MET in lung cancerAlex Friedlaender, Alexander Drilon, Giuseppe Luigi Banna, et al.
Current Oncology Reports|May 30, 2023
Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung CancerJay Parekh, Kaushal Parikh, Joshua E Reuss, et al.
Biomarker Research|February 12, 2024
Oncogenic alterations in advanced NSCLC: a molecular super-highwayAlex Friedlaender, Maurice Perol, Giuseppe Luigi Banna, et al.
Pageof 11